Genetic Susceptibility to Periprosthetic Joint Infections
Launched by UNIVERSITY OF UTAH · Dec 2, 2021
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is looking at genetics to understand why some people who have hip or knee replacement (total joint arthroplasty) develop an infection around the new joint, called a periprosthetic joint infection (PJI). It’s an observational, family-focused study, meaning researchers will follow families with a higher-than-normal chance of PJI to see if certain genes or genetic patterns are linked to the risk. Participants will provide DNA samples (blood or saliva) so scientists can look for genetic factors that might influence infection risk. The goal is to someday use this information to help prevent PJI in high-risk people.
Who can join: adults aged 18–100, both men and women, who are part of families with a higher risk of PJI after joint replacement (including unaffected relatives up to a third degree). The study will enroll about 150 people and is conducted by the University of Utah. Participation involves a genetic sample (blood draw or saliva/cheek cell) and no treatment is given as part of the study. Enrollment is by invitation, the study is ongoing with an estimated completion around 2028, and results will be used to improve understanding of genetic factors in PJI for future care. If you’re interested or have questions, the study team can be contacted through the listed investigators at the University of Utah.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Families/pedigrees which demonstrate a high-risk for PJI
- • Unaffected family members, up to 3rd degree
- Exclusion Criteria:
- • None
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Jeremy Gililland, M.D.
Principal Investigator
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials